Reactions Weekly

, Volume 1695, Issue 1, pp 76–76 | Cite as

Blinatumomab/protein tyrosine kinase inhibitors

Headache and ulnar neuropathy: 2 case reports
Case report


  1. Sokolov AN, et al. Blinatumomab + tyrosine kinase inhibitors with no chemotherapy in BCR-ABL-positive or ikzf1-deleted or FLT3-ITD-positive relapsed/refractory acute lymphoblastic leukemia patients: High molecular remission rate and toxicity profile. Blood 130 (Suppl. 1): Dec 2017. Available from: URL: -Russia

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations